Fig 1.
Illustrative image of the CALIPER of a patient with SSc and ILD.
Images were taken at time 0 (Fig 1A and 1B) and 24 months (Fig 1C and 1D). The individual voxels of lung regions in the original sections (A and C) are sorted and color-coded into one of the classes of visible abnormalities (B and D). (Image from the author’s personal archive).
Table 1.
Clinical characteristics of SSc patients according to the presence or absence of interstitial lung disease (ILD) at baseline.
Table 2.
Pulmonary function test (PFT) and pulmonary parameters quantified (qCT) by CALIPER at baseline and at 24 months of follow-up.
Table 3.
Forced vital capacity (FVC) and pulmonary parameters quantified (qCT) by CALIPER according to < 20% or > 20% of ILD extent using the Goh’s staging system.
Fig 2.
Survival compared between subgroups of patients with (A) ILD extent levels ≥ or < 6.32%; (C) reticular (RET) pattern ≥ or < 1.41% and (E) FVC ≥ or < 70% at baseline. Survival compared between subgroups of patients with (B) ILD extent ≥ or < 4.75%; (D) RET pattern ≥ or < 4.34% and (F) PVV/LV% ≥ or < 2.8% at follow-up. Survival rates in patients with ILD extension of ≥ 6.32% at baseline was 100%, 75% and 69% at 1, 3 and 5 years and of 100% at 1, 3 and 5 years in patients with ILD extension < 6.32% (A). At follow-up, the survival rates in patients with ILD extension of ≥ 4.75 was 100%, 93% and 71% at 1, 3 and 5 years and of 100% at 1, 3 and 5 years in patients with ILD extension of < 4.75 (B). Patients with a RET pattern ≥ 1.41% at baseline had survival of 100%, 77% and 71% at 1, 3 and 5 years and of 100%,96% and 96% at 1, 3 and 5 years in patients with RET < 1.41% (C). In patients with a RET pattern of ≥ 4.34 at follow-up the survival rates were 100%, 44% and 44% at 1, 3 and 5 years and of 100%, 91% and 87% at 1, 3 and 5 years in patients with RET pattern of < 4.34 (D). In patients with a FVC ≥ 70% at baseline the survival at 1,3 and 5 years was 100, 92 and 92% and of 100%, 77% and 70% in those with FVC < 70% (E). At follow-up, the survival rates in patients with PVV/LV ≥ 2.8 was 100%, 75% and 68% at 1, 3 and 5 years and of 100%, 96% and 96% at 1, 3 and 5 years in those with a PVV/LV <2.8 (F).
Table 4.
Univariate analysis of clinical, functional and anatomical characteristics and risk of death.
Table 5.
Multivariate assessment between sex, age, ground-glass (%) and reticular pattern (%) at baseline and FVC decline ≥5% pred at 24 months in predicting mortality.